PDCD1 and glioblastoma: Despite the promising results of immune checkpoint blockade on other cancer types including metastatic disease to the brain [115,116,117,118], immune checkpoint monotherapy targeting the PD-1/PD-L1 axis has limited success in recurrent GBM (Checkmate-143 trial; NCT02017717) [19,123].